Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
复制标题
DOI：
10.1007/s00296-021-05017-9
复制
发表时间：
2021-12
影响因子：
4
通讯作者：
Galarza-Delgado DA
中科院分区：
文献类型：
--
作者：
Esquivel-Valerio JA;Skinner-Taylor CM;Moreno-Arquieta IA;Cardenas-de la Garza JA;Garcia-Arellano G;Gonzalez-Garcia PL;Almaraz-Juarez FDR;Galarza-Delgado DA
关于COVID-19疫苗在自身免疫性和炎症性风湿病（AIIRD）患者中的疗效和不良事件（AE）的数据最近已经发表，尽管这些数据主要包括mRNA疫苗（辉瑞- biontech和Moderna）和ChAdOx1 nCoV-19/AZD1222（牛津-阿斯利康）。本研究旨在研究6种不同的SARS-CoV-2疫苗（ChadOX1 nCoV-19 （AZD1222）、Ad5-nCoV2、Ad26.COV2）引起的AE的流行情况。S、mRNA-1273、BNT162b2和CoronaVac}在墨西哥AIIRD患者中的作用。我们对疫苗史进行了横断面研究。连续招募225例患者，平均年龄50.7岁，大多数（n = 213, 94.6%）为女性。107例（47.5%）收到BNT162b2 mRNA， 34例（15.1%）收到Ad5-nCoV mRNA， 29例（12.8%）收到mRNA-1273 mRNA， 28例（12.4%）收到ChAdOX1 nCoV-19 (AZD1222) mRNA， 22例（9.7%）收到CoronaVac mRNA， 5例（2.2%）收到ad26 . cov . s mRNA。与接种人数成比例AE发生率最高的疫苗是杨森（5;100%），其次是辉瑞- biontech（86; 80%）和康西诺（27;79.4%）。局部疼痛是最常见的AE（158例，70.2%）。疲劳（78例，34.7%）、头痛（69例，30.6%）和肌肉疼痛（66例，29.3%）是最常见的全身症状。没有严重的AE需要医疗或住院治疗的报告。目前的结果支持不同的COVID-19疫苗对AIIRD患者的安全性。这一信息有助于消除这一人群对疫苗的犹豫。
Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca). This research aimed to study the prevalence of AE presented with six different SARS-CoV-2 vaccines {ChadOX1 nCoV-19 (AZD1222), Ad5-nCoV2, Ad26.COV2.S, mRNA-1273, BNT162b2, and CoronaVac} in Mexican patients with AIIRD. We performed a cross-sectional study about vaccine history. Two hundred and twenty five consecutive patients were recruited, mean age was 50.7 years and the majority (n = 213; 94.6%) were females. One hundred and seven (47.5%) received BNT162b2 mRNA, 34 (15.1%) Ad5-nCoV, 29 (12.8%) mRNA-1273, 28 (12.4%) ChAdOX1 nCoV-19 (AZD1222), 22 (9.7%) CoronaVac and 5 (2.2%) Ad26.COV2.S. The vaccines that had the most AE proportionally to the number of patients vaccinated were Janssen (5; 100%) followed by Pfizer-BioNTEch (86; 80%) and CanSinoBIO (27; 79.4%). Localized pain was the most frequent (158; 70.2%) AE. Fatigue (78; 34.7%), headache (69; 30.6%) and muscle ache (66; 29.3%) were the most common systemic symptoms. No serious AE that required medical attention or hospitalization were reported. The current results support the safety of different COVID-19 vaccines in patients with AIIRD. This information can help fight vaccine hesitancy in this population.
登录
查看更多内容
影响因子：
4.5
作者：
Gaur PS;Zimba O;Agarwal V;Gupta L
通讯作者：
Gupta L
影响因子：
12
作者：
Urrunaga-Pastor D;Bendezu-Quispe G;Herrera-Añazco P;Uyen-Cateriano A;Toro-Huamanchumo CJ;Rodriguez-Morales AJ;Hernandez AV;Benites-Zapata VA
通讯作者：
Benites-Zapata VA
影响因子：
4
作者：
Cherian S;Paul A;Ahmed S;Alias B;Manoj M;Santhosh AK;Varghese DR;Krishnan N;Shenoy P
通讯作者：
Shenoy P
影响因子：
4
作者：
Gaur P;Agrawat H;Shukla A
通讯作者：
Shukla A
影响因子：
2.6
作者：
da Rosa Mesquita R;Francelino Silva Junior LC;Santos Santana FM;Farias de Oliveira T;Campos Alcântara R;Monteiro Arnozo G;Rodrigues da Silva Filho E;Galdino Dos Santos AG;Oliveira da Cunha EJ;Salgueiro de Aquino SH;Freire de Souza CD
通讯作者：
Freire de Souza CD